Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

BEIJING, May 06, 2024--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG ("BioCopy"), a research-based biotechnology company headquartered in Basel, Switzerland.

Related Keywords

United States ,Shanghai ,China ,Switzerland ,San Francisco ,California ,Beijing ,Heidelberg ,Baden Wüberg ,Germany ,Haimen Jiangsu ,Yuelei Shen ,Biocytogen Pharmaceuticals Beijing Co Ltd , ,Biocytogen Pharmaceuticals ,Antibody Discovery ,Biocopy Ag ,Novel Cancer Therapies ,Human Antibody ,Research And Development ,Antibody Screening ,